HRP20241213T1 - Primjena sepiapterina bez hrane za uporabu u postupku za povećavanje plazmatske izloženosti sepiapterinu - Google Patents
Primjena sepiapterina bez hrane za uporabu u postupku za povećavanje plazmatske izloženosti sepiapterinu Download PDFInfo
- Publication number
- HRP20241213T1 HRP20241213T1 HRP20241213TT HRP20241213T HRP20241213T1 HR P20241213 T1 HRP20241213 T1 HR P20241213T1 HR P20241213T T HRP20241213T T HR P20241213TT HR P20241213 T HRP20241213 T HR P20241213T HR P20241213 T1 HRP20241213 T1 HR P20241213T1
- Authority
- HR
- Croatia
- Prior art keywords
- sepiapterin
- pharmaceutically acceptable
- acceptable salt
- food
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677943P | 2018-05-30 | 2018-05-30 | |
| US201862771398P | 2018-11-26 | 2018-11-26 | |
| US201962822376P | 2019-03-22 | 2019-03-22 | |
| GC201937663 | 2019-05-28 | ||
| EP19811888.7A EP3801536B1 (en) | 2018-05-30 | 2019-05-30 | Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure |
| PCT/US2019/034523 WO2019232130A1 (en) | 2018-05-30 | 2019-05-30 | Methods for increasing sepiapterin plasma exposure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241213T1 true HRP20241213T1 (hr) | 2024-11-22 |
Family
ID=68699037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241213TT HRP20241213T1 (hr) | 2018-05-30 | 2019-05-30 | Primjena sepiapterina bez hrane za uporabu u postupku za povećavanje plazmatske izloženosti sepiapterinu |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11617752B2 (https=) |
| EP (2) | EP4454704A3 (https=) |
| JP (2) | JP7502197B2 (https=) |
| CN (1) | CN112703002A (https=) |
| AU (2) | AU2019277382B2 (https=) |
| CA (1) | CA3102106A1 (https=) |
| DK (1) | DK3801536T3 (https=) |
| ES (1) | ES2986920T3 (https=) |
| FI (1) | FI3801536T3 (https=) |
| HR (1) | HRP20241213T1 (https=) |
| HU (1) | HUE068589T2 (https=) |
| LT (1) | LT3801536T (https=) |
| MD (1) | MD3801536T2 (https=) |
| MX (2) | MX2020012979A (https=) |
| PL (1) | PL3801536T3 (https=) |
| PT (1) | PT3801536T (https=) |
| RS (1) | RS65874B1 (https=) |
| SI (1) | SI3801536T1 (https=) |
| SM (1) | SMT202400430T1 (https=) |
| WO (1) | WO2019232130A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| FI3801536T3 (fi) | 2018-05-30 | 2024-08-29 | Ptc Therapeutics Mp Inc | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi |
| EP3801534B1 (en) | 2018-05-30 | 2026-02-18 | PTC Therapeutics MP, Inc. | Treatment of phenylketonuria with sepiapterin |
| EP4093405A1 (en) * | 2020-01-24 | 2022-11-30 | PTC Therapeutics MP, Inc. | Methods for treating parkinson's disease with sepiapterin |
| WO2021168206A1 (en) * | 2020-02-19 | 2021-08-26 | Musc Foundation For Research Development | L-sepiapterin and methods of use for treating diseases and disorders |
| IL305037A (en) * | 2021-02-09 | 2023-10-01 | Ptc Therapeutics Mp Inc | Methods of treating glioblastomas with spiafatrin |
| WO2022173823A1 (en) * | 2021-02-09 | 2022-08-18 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
| CN120732846A (zh) * | 2025-04-09 | 2025-10-03 | 中南大学湘雅医院 | 吲哚乙酸在制备预防或治疗高血压产品中的用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| JP2002515965A (ja) | 1995-08-18 | 2002-05-28 | ダブリュー． ランドリ，ドナルド | 抗体触媒反応の調節による有機化合物の検出 |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| WO2005048926A2 (en) | 2003-11-13 | 2005-06-02 | The General Hospital Corporation | Methods for treating pain |
| EP1687308B1 (en) | 2003-11-17 | 2019-06-12 | Merck & Cie | Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms |
| PL1708690T3 (pl) | 2003-11-17 | 2017-01-31 | Biomarin Pharmaceutical Inc. | Leczenie fenyloketonurii za pomocą BH4 |
| JP5184783B2 (ja) | 2003-11-17 | 2013-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法 |
| KR20070084270A (ko) | 2004-11-17 | 2007-08-24 | 바이오마린 파머수티컬 인크. | 안정한 정제 제형물 |
| JP2008523090A (ja) | 2004-12-08 | 2008-07-03 | バイオマリン ファーマシューティカル インコーポレイテッド | 新生児肺高血圧症の治療のための方法および組成物 |
| BRPI0609421B1 (pt) | 2005-04-28 | 2021-06-01 | Shiratori Pharmaceutical Co., Ltd. | Processos para produção de um composto 1,1-bis-alquil sulfonila, para produção de um composto aldeído, e para produção de um derivado de hidrazona |
| US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| LT2545939T (lt) | 2007-04-11 | 2021-03-10 | Biomarin Pharmaceutical Inc. | Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu |
| WO2010017570A2 (de) | 2008-08-12 | 2010-02-18 | Orpha Swiss Gmbh | Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin |
| EP2562176B1 (en) * | 2010-04-22 | 2018-08-15 | Nihon University | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| CN103458900A (zh) | 2011-03-01 | 2013-12-18 | 鲁必康研究私人有限公司 | 四氢生物蝶呤的稳定组合物 |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| CN104736539B (zh) | 2012-05-07 | 2017-09-01 | 白鸟制药株式会社 | 墨蝶呤和四氢乳酰蝶呤的制造法 |
| EP3213062B1 (en) * | 2014-10-31 | 2020-02-12 | Children's Medical Center Corporation | Methods and assays relating to sepiapterin reductase inhibition |
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| WO2019102315A1 (en) * | 2017-11-23 | 2019-05-31 | Semiconductor Energy Laboratory Co., Ltd. | Display device and electronic device |
| EP3801534B1 (en) * | 2018-05-30 | 2026-02-18 | PTC Therapeutics MP, Inc. | Treatment of phenylketonuria with sepiapterin |
| AU2019277372B2 (en) | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| FI3801536T3 (fi) | 2018-05-30 | 2024-08-29 | Ptc Therapeutics Mp Inc | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi |
| IL290321B1 (en) | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
-
2019
- 2019-05-30 FI FIEP19811888.7T patent/FI3801536T3/fi active
- 2019-05-30 CN CN201980050839.7A patent/CN112703002A/zh active Pending
- 2019-05-30 MX MX2020012979A patent/MX2020012979A/es unknown
- 2019-05-30 HR HRP20241213TT patent/HRP20241213T1/hr unknown
- 2019-05-30 SI SI201930841T patent/SI3801536T1/sl unknown
- 2019-05-30 LT LTEPPCT/US2019/034523T patent/LT3801536T/lt unknown
- 2019-05-30 EP EP24187175.5A patent/EP4454704A3/en active Pending
- 2019-05-30 PL PL19811888.7T patent/PL3801536T3/pl unknown
- 2019-05-30 US US17/059,719 patent/US11617752B2/en active Active
- 2019-05-30 JP JP2020566655A patent/JP7502197B2/ja active Active
- 2019-05-30 EP EP19811888.7A patent/EP3801536B1/en active Active
- 2019-05-30 RS RS20240943A patent/RS65874B1/sr unknown
- 2019-05-30 CA CA3102106A patent/CA3102106A1/en active Pending
- 2019-05-30 MD MDE20210340T patent/MD3801536T2/ro unknown
- 2019-05-30 HU HUE19811888A patent/HUE068589T2/hu unknown
- 2019-05-30 AU AU2019277382A patent/AU2019277382B2/en active Active
- 2019-05-30 PT PT198118887T patent/PT3801536T/pt unknown
- 2019-05-30 WO PCT/US2019/034523 patent/WO2019232130A1/en not_active Ceased
- 2019-05-30 ES ES19811888T patent/ES2986920T3/es active Active
- 2019-05-30 DK DK19811888.7T patent/DK3801536T3/da active
- 2019-05-30 SM SM20240430T patent/SMT202400430T1/it unknown
-
2020
- 2020-11-30 MX MX2024005935A patent/MX2024005935A/es unknown
-
2023
- 2023-03-31 US US18/129,177 patent/US12329757B2/en active Active
-
2024
- 2024-02-05 JP JP2024015822A patent/JP7841005B2/ja active Active
-
2025
- 2025-02-06 AU AU2025200814A patent/AU2025200814A1/en active Pending
- 2025-05-13 US US19/206,193 patent/US20260091037A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3801536A4 (en) | 2022-03-23 |
| CA3102106A1 (en) | 2019-12-05 |
| SI3801536T1 (sl) | 2024-12-31 |
| DK3801536T3 (da) | 2024-08-19 |
| LT3801536T (lt) | 2024-09-25 |
| JP2024069192A (ja) | 2024-05-21 |
| ES2986920T3 (es) | 2024-11-13 |
| PL3801536T3 (pl) | 2025-02-03 |
| FI3801536T3 (fi) | 2024-08-29 |
| US11617752B2 (en) | 2023-04-04 |
| EP4454704A3 (en) | 2025-01-01 |
| US20230381181A1 (en) | 2023-11-30 |
| US12329757B2 (en) | 2025-06-17 |
| MD3801536T2 (ro) | 2024-11-30 |
| JP2021525729A (ja) | 2021-09-27 |
| AU2019277382A1 (en) | 2021-01-21 |
| CN112703002A (zh) | 2021-04-23 |
| WO2019232130A1 (en) | 2019-12-05 |
| AU2019277382B2 (en) | 2025-01-09 |
| SMT202400430T1 (it) | 2024-11-15 |
| HUE068589T2 (hu) | 2025-01-28 |
| PT3801536T (pt) | 2024-09-19 |
| JP7841005B2 (ja) | 2026-04-06 |
| US20260091037A1 (en) | 2026-04-02 |
| MX2020012979A (es) | 2021-04-29 |
| EP3801536B1 (en) | 2024-07-17 |
| RS65874B1 (sr) | 2024-09-30 |
| AU2025200814A1 (en) | 2025-02-27 |
| EP3801536A1 (en) | 2021-04-14 |
| US20210220363A1 (en) | 2021-07-22 |
| EP4454704A2 (en) | 2024-10-30 |
| MX2024005935A (es) | 2024-06-04 |
| JP7502197B2 (ja) | 2024-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241213T1 (hr) | Primjena sepiapterina bez hrane za uporabu u postupku za povećavanje plazmatske izloženosti sepiapterinu | |
| HRP20251261T1 (hr) | Inhibitori csf1r za uporabu u liječenju tenosinovijalnih gigantocelularnih tumora | |
| HRP20250480T1 (hr) | Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća | |
| HRP20221269T1 (hr) | Pripravci za liječenje mijelofibroze | |
| HRP20231142T3 (hr) | Kontrolirano oslobađanje 25-hidroksivitamina d | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| RS65359B1 (sr) | Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanja | |
| JP5902628B2 (ja) | 相乗的抗ウイルス組成物及びその使用 | |
| HRP20250972T1 (hr) | Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak | |
| EA008165B1 (ru) | Композиции для лечения простуды | |
| JP2021525729A5 (https=) | ||
| FI3370692T3 (fi) | Nenän tukkoisuutta poistava koostumus, jolla on antiviraalinen aktiivisuus | |
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| PE20081578A1 (es) | Formulacion en polvo de valganciclovir | |
| HRP20230935T1 (hr) | Postupci za liječenje i profilaksu hiv-a i aids-a | |
| MY209220A (en) | Dosing regimen for the treatment of pi3k related disorders | |
| NO20075945L (no) | Behandling, prevensjon og ameliorasjon av lungelidelser assosiert med kjemoterapi eller radioterapi med aktive vitamin D sammensetninger eller imitatorer derav | |
| HK1252411A1 (zh) | 磷脂酰肌醇3-激酶抑制剂的给药方案 | |
| HRP20211661T1 (hr) | Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti | |
| HRP20250052T1 (hr) | Postupak liječenja multiple skleroze | |
| Schreck | Asthma pathophysiology and evidence-based treatment of severe exacerbations | |
| HRP20230735T1 (hr) | Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta | |
| US20060105036A1 (en) | Threo-dops controlled release formulation | |
| JP2016539167A (ja) | ダントロレンの髄腔内投与による痙縮の治療 | |
| HRP20221034T1 (hr) | Aklidinij za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća |